Abstract | Osteoarthritis (OA), the most common musculoskeletal disorder, is complex, multifaceted, and characterized by degradation of articular cartilage and alterations in other joint tissues. Although some pathogenic pathways have been characterized, current knowledge is incomplete and effective approaches to the prevention or treatment of OA are lacking. Understanding novel molecular mechanisms that are involved in the maintenance and destruction of articular cartilage, including extracellular regulators and intracellular signalling mechanisms in joint cells that control cartilage homeostasis, has the potential to identify new therapeutic targets in OA. MicroRNAs control tissue development and homeostasis by fine-tuning gene expression, with expression patterns specific to tissues and developmental stages, and are increasingly implicated in the pathogenesis of complex diseases such as cancer and cardiovascular disorders. The emergent roles of microRNAs in cartilage homeostasis and OA pathogenesis are summarized in this Review, alongside potential clinical applications.
Introduction
OA pathology Approximately 40 million Americans were affected by OA as of 2008, a number predicted to increase to 60 million within the next 20 years as a result of population ageing and an increase in life expectancy. 1, 2 In contrast to the replacement of cartilage with bone-endochondral ossification-that occurs during skeletal development, chondrocyte populations in articular cartilage persist and continue to maintain joint tissue into adulthood. OA is associated with age-related loss of homeostatic balance between degradation and repair mechanisms in articular cartilage. [3] [4] [5] This dysregulation induces senescence, differen tiation, proliferation and cell death in joint cells through gene and/or protein expression networks that switch from anabolic to catabolic outcomes ( Figure 1 ). Cartilage-degrading enzymes such as a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, ADAMTS-5 and matrix metalloproteinase (MMP)-13 are known to be critical enzymes in OA pathogenesis. [3] [4] [5] Nevertheless, available treatments for OA are limited to pain management, and, in the late phase of the disease process, joint-replacement surgery is often indicated. Pharmacologic interventions that alter the progressive loss of articular cartilage are not available. In this whole-joint disorder that manifests with cartilage degradation, abnormal subchondral bone remodelling, synovial hyperplasia, increased inflammatory mediator content, fibrosis of the joint capsule, angiogenesis in various joint tissues and changes in menisci and ligaments, 6 therefore, advances toward understanding the molecular mechanisms that maintain whole-joint health are required.
Genetic regulation by microRNA microRNAs (miRNAs) are a class of endogenous noncoding small RNAs that fine-tune expression of multiple genes to maintain cellular function ( Figure 2 ). miRNAs promote the degradation and/or repress the translation of messenger RNA (mRNA) through sequencespecific interactions with the 3' untranslated regions (UTRs) of specific mRNA targets, [7] [8] [9] and studies have also identified miRNA-binding sites within the 5'-UTRs and coding regions of target genes. 10 Transcription factors such as myoblast determination protein 1, myogenin 11 and nuclear factor κB 12 control transcription of primary miRNA transcripts, which are processed by the microprocesor complex-which comprises ribonuclease 3 (also known as Drosha) and DGCR8-to form a hairpin precursor miRNA (pre-miRNA) of ~60 nucleotides in length. Pre-miRNAs are processed by the endoribonuclease Dicer, to form ~22-nucleotidelong, functionally mature miRNAs. Complexed with protein argonaute-2, the core unit of the RNA-induced silencing complex (RISC), [7] [8] [9] the miRNAs bind target mRNAs and mediate their translational repression or degradation ( Figure 2 ). [13] [14] [15] [16] Dysregulated expression of miRNAs can result from altered transcription factor activity, epigenetic changes, and/or processing and genetic alterations that affect production of the primary miRNA transcript, 17 and can cause disease by disrupting the expression network of their target genes ( Figure 1) . A single miRNA can influence the same biological process in multiple subtle ways, through guiding the RISC to several different mRNAs and inducing modest re pression of their expression (Figure 2) .
Hundreds of miRNAs have been found in various organisms, and many miRNAs are evolutionarily conserved. Moreover, one-third of all mammalian mRNAs seem to be under miRNA regulation. 18 The importance of miRNAs in development and differentiation has been shown by loss-of-function analyses of Dicer, argonaute-2 and Dgcr8 in mice, which result in embryonic-lethal or severe developmental defects as a consequence of cellcycle arrest and differentiation problems. [19] [20] [21] Furthermore, limb-specific and cartilage-specific deletion of Dicer highlighted the role of miRNAs in the musculoskeletal system: mice with these deletions had smaller limbs or bodies than age-matched control mice as a consequence of chondrocyte proliferation, accelerated hypertrophic differentiation and subsequent cell death. 22, 23 Osteoclast-specific deletion of Dicer in mice increased bone mass by regulating bone resorption. 24 miRNA in disease Highly specific patterns of miRNA expression correlate with development and several diseases such as cancer 25 and cardiovascular disorders, 26 and tissue-specific miRNA functional studies in mice have revealed both pathogenic and protective functions. 27 These insights suggest the potential for therapeutic manipulation of miRNAs, using antisense miRNA or double-stranded miRNA mimics, and for their use as diagnostic markers in various diseases (Figure 1) . Indeed, miRNA treatment in primates with chronic hepatitis C virus (HCV) infection demonstrated the feasibility of prolonged administration of a synthetic antisense miRNA drug-which antagonizes the function of a specific miRNA implicated in liver-cell accumulation of HCV RNA-resulting in improvements in HCV-induced liver pathology. 28 It would seem, therefore, that miRNA-based drugs and/or targeting miRNAs might not be far from clinical development in some diseases, whereas much less is known about the pathophysiological role of miRNA in OA. Nevertheless, several miRNAs are implicated in the maintenance of healthy cartilage and/or in OA pathogenesis (Table 1) . Furthermore, methods for targeting miRNA are in development in several fields, and it is hoped they can be rapidly applied to OA. In this Review, we outline the miRNAs that have been implicated in maintaining cartilage health, in pathogenesis in animal Key points ■ Although some pathogenic pathways in osteoarthritis (OA) have been characterized, effective approaches to prevention or treatment of OA are lacking ■ Novel genetic regulators, microRNAs (miRNAs), are involved in the development of the musculoskeletal system and OA pathogenesis through maintenance of articular chondrocytes ■ miRNAs have a role in transmitting the effects of the main risk factors for OA, such as ageing and inflammation, onto cellular homeostasis through their control of multiple target genes ■ Approaches to maintaining or suppressing the expression of key miRNAs in OA pathogenesis have the potential to identify new therapeutic and diagnostic targets models of OA, and in patients with OA. We focus on miR-140 as an example, as data from animal studies of this molecule are among the most advanced currently available in OA. In the final section, we discuss the clinical potential of miRNAs and the unique challenges of delivering them to joint tissues.
miRNA in cartilage, bone and OA miRNA in cartilage and bone development As we have discussed, knockout of Dicer (which is indispensable for producing mature miRNA) in mouse cartilage or limbs causes reduced limb size with normal patterning, and suggests that specific miRNAs have critical roles in bone-cartilage development. 22, 23 In zebrafish, cartilage-specific expression of miR-140 has been shown, 29 and implicated in palatogenesis through repression of signalling by platelet-derived growth factor. 30 miR-140 is expressed in the cartilage of mouse embryos during development of long and flat bones, and directly regulates expression of the gene encoding histone deacetylase 4 (Hdac4). 31 Using miRNA microarrays to profile and compare miRNA expression between human articular cartilage chondrocytes and bone marrow-derived mesenchymal stem cells (MSCs), our group identified miR-140 as the most differentially expressed of several miRNAs that were more abundant in articular cartilage as compared with undifferentiated MSCs. 32 Mouse whole-mount in situ hybridization data probing for miR-140 are consistent with this tissue specificity of miR-140. 31, 33 Expression of miR-140 increased in parallel with the expression of chondrogenic markers such as Sox9 and Col2a1 during chondrogenesis of MSCs in pellet cultures, 32 whereas its expression was reduced in dedifferen tiated human chondrocytes with each passage (H. Asahara, unpublished data). Lin et al. 34 examined the expression pattern of miRNA in primary and dedifferentiated adult human articular chondrocytes; their results showed a dramatic change in expression of miRNA between the two cell types. Among the most notable changes were in the expression of miR-491 and miR-140, which was upregulated in primary chondrocytes. 34 We generated mice deficient in miR-140, which are born normal and are fertile, with skeletal development during embryogenesis seeming grossly normal. Postnatally, however, these mice manifest a mildly abnormal skeletal phenotype of short stature and cranio facial deformities as a result of impaired chondrocyte homeostasis and proliferation. 35 Another group separately generated mice deficient in miR-140, and reported a similar skeletal phenotype. 36 These investigators compared profiles of miRNA in complex with argonaute-2 between wild-type and miR140-null chondrocytes, and showed that expression of Dnpep (encoding aspartyl aminopeptidase) was upregulated in cells lacking miR-140. This upregulation mildly antagonized signalling by bone morphogenetic protein (Bmp) downstream of Smad activation, implicating this pathway in causing the skeletal defects of miR-140-deficient mice. 36 Similarly, knockdown of miR-140 in limb-bud micromass cultures resulted in arrest of chondrogenic prolifera tion by regu lating Sp1 (encoding transcription factor Sp1), again acting downstream of Bmp signalling. 37 Furthermore, manipulation of miR-140 in chondrocytes altered chondro cyte expression of Bmp2 and BMP2 in mouse and human cells, respectively. 36, 38 The expression of miR-140 was found to be regulated by Sox9, known as a 'cartilage master regulator' for its roles in controlling production of the extracellular matrix (ECM), and by Sox family members Sox5 and Sox6. 33, 37, 39 Besides miR-140, expression of a few other miRNAs in chondrocytes has been shown ( Table 1) . miR-675, for example, is highly expressed in human articular chondro cytes, and its expression, in common with that of miR-140, also depends on SOX9. 40 miR-455, located in the intron of a cartilage collagen gene, is expressed during a cell culture model of chondrogenesis (alongside miR-140), and regulates transforming growth factor (TGF)-β signalling. 41 A 2012 study that used human chondrocytes reported that expression of SOX9 is itself regulated by an miRNA, miR-145, which binds a 3'-UTR site in SOX9 that is not conserved in the mouse gene. 42 Increased levels of miR-145 caused, via SOX9, the loss of a differentiated chondrocyte phenotype, with reduced expression of miR-140, miR-675 and cartilage ECM genes, and increased expression of markers of cartilage hypertrophy. 42 Perhaps reflecting the different regulation of human SOX9 and mouse Sox9, mice deficient in miR-145 are viable at birth and do not display any obvious disorders when kept in normal vivarium conditions; however, lack of miR-145 was implicated in aberrant response to vascular injury. 43 Altogether, it seems that miR-140 regulates endochondral bone development in mice by repressing multiple target genes in the Bmp and TGF-β signalling pathways, as well as helping to maintain articular cartilage homeostasis. Loss of this dual repression might contribute to the development of OA (Figure 3 ), as we discuss below.
Identifying a role for miRNA in OA Genetic factors with roles in tissue development are often implicated in disease states that involve loss of tissue homeostasis, and miRNAs are no exception. In 2008, Iliopoulos et al. 44 used genetic, bioinformatic and proteomic approaches to construct a potential 'i nteractome'-a metabolic network of 11 miRNA and 58 proteins potentially involved in OA pathogenesis -in a study involving 33 patients with OA. In total, 16 miRNAs were differentially expressed in OA compared with normal cartilage; nine, including miR-22 and miR-103, were upregulated and the 'top two' among seven that were downregulated in OA cartilage samples were miR-29a and miR-140. No change to miR-146 expression was reported in this study, and the functions of most of the transcripts identified are as yet unclear. 44 Jones et al. fourfold differen tial expression between OA and normal cartilage and bone samples. miR-9, miR-34 and miR-98 were upregulated in both OA cartilage and OA bone tissue, miR-146 was downregulated in OA cartilage. Most miRNAs identified in these data 45 did not match those in the data of Iliopoulos et al., 44 reflecting that profiling gene expression changes in cartilage from human donors is difficult because the properties of cartilage in OA depend on the cartilage region and grade of OA severity.
In our data, miR-140 was highly expressed in normal human articular chondrocytes, and its expression was significantly reduced in cartilage from patients with OA (P = 0.017). 32 Tardif et al. 46 also reported that expression of miR-140 was significantly reduced in chondrocytes from patients with OA in comparison with healthy controls (P <0.01). Furthermore, in vitro treatment of chondro cytes with IL-1β, a cytokine classically involved in OA pathogenesis, suppresses miR-140 expression. 32 These data, together with the findings discussed above that show a role for miR-140 in endochondral bone development in mice, implicate regulation of miR-140 in OA pathogenesis. miRNA in OA mechanisms Risk factors for OA progression include ageing, joint injury, excessive chronic mechanical stress and inflammation, [3] [4] [5] and the expression of several miRNAs that are implicated in OA is regulated by these factors. Indeed, the functions of miRNA often only become clear under conditions of stress. Different animal models of OA are thought to mimic the human disease that results from these factors, and in this section we discuss miRNA that are implicated in these different aspects of OA pathology. Again, we use animal studies of miR-140 by our group as a paradigm for studies of miRNA in OA.
Ageing
Ageing is one of the most important risk factors for OA. Among joint tissues, articular cartilage is the most susceptible to damage and exhibits remarkable ageingrelated changes in humans and animal models. Although relationships between miRNA expression patterns and the ageing process are not fully understood, several studies have provided evidence that miRNAs are associated with ageing. 47 miRNA expression is predominantly more upregulated than downregulated in livers of mice during ageing, and parallel proteomic pro filing and bioinformatic mapping studies show that the upregulated miRNA expression corresponds to down regulation of genes functionally involved in the control of intermediate metabolism, apoptosis, DNA repair, oxidative defense (particularly mitochondrial oxidative phosphorylation) and other pathways implicated in ageing. is increasingly recognized as a critical regulator of stress responses, replicative senescence, inflammation, metabolism and ageing in chondrocytes. [49] [50] [51] The expression of SIRT1 is decreased in cartilage and chondrocytes from patients with OA 52 and its expression regulates apoptosis and the expression of chondrogenic and OA-related genes in cells and tissues from mice. 52, 53 Expression of SIRT1 is controlled by miRNAs; several, such as miR-9, miR-22, miR-34 and miR-181, suppress SIRT1 expression in various cells. [54] [55] [56] Levels of miR-22 are upregulated during cardiac ageing, in fibroblasts and epithelial cells.
56,57 miR-34a is upregulated by IL-1β and its silencing in rats inhibited IL-1β-induced up-regulation of inducible nitric oxide synthase expression and chondrocyte apoptosis. 58 The expression of miR-9, miR-22 and miR-34 is upregulated in cartilage from patients with OA (age range 57-83 years, n = 33; 44 age range 66-71 years n = 3 45 ), suggesting that ageing, miRNA and SIRT1 might form a key signalling cascade in OA pathogenesis. Mice deficient in miR-140 exhibited early onset of ageing-related OA-like changes compared with wild-type mice, despite joint structures appearing normal at birth and at 1 month of age. 35 Mechanical stress An appropriate amount of mechanical stress is known to be required for cartilage homeostasis; however, excessive mechanical loads due to joint trauma can lead to acute post-traumatic arthritis, and, in many cases, OA develops as a long-term complication. 3 Furthermore, using surgical resection of the medial meniscotibial ligament to destabilize the joint and cause excessive mechanical load (the surgical OA model), our group found that miR-140 deficient mice exhibited accelerated proteoglycan loss and fibrillation of articular cartilage in knee joints, compared with wild-type mice, at 8 weeks after surgery. 35 Understanding the mechanotransduction pathway in chondrocytes might be one way of approaching pharmaco logical control of cartilage homeostasis, and miRNAs are also implicated in this aspect of OA. For example, preliminary studies indicate that miR-222 expression patterns in bovine articular cartilage are higher in the weight-bearing area as compared with the non-weight-bearing area. Thus, miR-222 might be a potential regulator of the articular cartilage mechanotransduction pathway. 59 
Inflammation and cartilage homeostasis
It is well known that inflammatory cytokines, including TNF and IL-1β, are upregulated in arthritic joint tissue (and in the acute post-traumatic inflammatory response), and that cell signalling triggered by these effectors disrupts articular cartilage homeostasis. 4, 5 Increased IL-1 expression after mechanical joint injury or during OA development correlates with the severity of cartilage damage. 3, 5 Animal model and cell-study data in OA again implicate miRNAs in control of these inflam matory pathways. Several miRNAs have been implicated in pathways linking inflammation and rheumatoid arthritis (RA), 60 but little is known about how cartilage-specific genes including miRNAs are downregulated by inflammatory cytokine stimulation. For example, miR-146 was found to be overexpressed in RA synovium. 61, 62 In several cell types, its expression was inducible in response to application of inflammatory factors such as cytokines, and a negative feedback loop ensued, involving downregulation of IL-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associat ed factor 6 (TRAF6) (Figure 4) . 12 In cartilage samples from a total of 15 patients with OA, miR-146a was expressed in grade I (mild) OA cartilageparticularly in superficial-layer articular chondrocytes -at a level significantly higher than the levels in stage II Figure 3 | Dual roles of miR-140 in endochondral bone development and articular cartilage homeostasis. A common mechanism of miRNA function involves the modest repression of several mRNA transcripts involved in the same biological process by a single miRNA. 26 However, miR-140 has roles in both endochondral bone development and articular cartilage homeostasis by repressing multiple target genes, and miR-140 at the osteochondral junction might be associated with OA progression by maintaining cartilage-bone differentiation. Abbreviations: miRNA, microRNA; mRNA, messenger RNA; OA, osteoarthritis.
(moderate) and III (severe) OA samples (P <0.05). This stage-related pattern mirrored that of MMP13 expression, and the investigators found that stimulation of cultured normal articular chondrocytes with IL-1β markedly increased expression of miR-146a. 63 In another study in isolated human chondrocytes, overexpression of miR-146 reduced the IL-1β-induced production of TNF. 45 In miRNA profiling of IL-1β-stimulated OA chondrocytes, stimulation with IL-1β downregulated the expression of 42 miRNAs, had no effect on the expression of 308 miRNAs, and upregulated the expression of only miR-146 and miR-491. 64 Downregulated miR-27b directly tar gets and downregulates Mmp-13 expression. 64 In the study by Iliopoulos et al. introduced above, 44 miR-22 and miR-103 were among miRNAs with upregu lated expression in OA cartilage, and their level was found to correlate with BMI. Validation experiments in healthy and OA chondrocytes showed that miR-22 directly regulates PPARA and BMP7 expression, and its upregulation induced inflammatory and catabolic changes in the cells. 44 miR-9 and miR-98 were found to inhibit secretion of MMP-13 and TNF in IL-1β-stimulated human chondrocytes from three patients with OA. 45 In contrast to findings in cartilage, miR-146a is expressed at reduced levels in dorsal root ganglion cells and at the dorsal horn of spinal cords isolated from rats experiencing experimental OA-induced pain. Thus, this miRNA potentially controls knee joint homeostasis and OA-associated algesia by balancing inflammatory responses in cartilage and synovium with pain-related factors in glial cells. 65 In antigen-induced arthritis (AIA), transient joint inflammation rapidly causes cartilage degradation in wild-type animals by the induction of cartilagedegrading enzymes in chondrocytes. Although most applicable as an animal model of RA, AIA enables monitor ing of the potential protective effects of miRNAs against inflammation-induced cartilage degradation. Transgenic miR-140 mice were resistant to AIAassociated loss of proteo glycan and type II collagen compared with wild-type mice, 35 consistent with the idea that miR-140 might protect against inflammationinduced cartilage degradation. Regulation of Adamts5, a direct target of miR-140, might explain a substantial part of the protective mechanism, 35 but miRNAs regulate multiple target mRNAs.
Bone metabolism
Although OA is often characterized as a disease of articular cartilage, the alternation of bone metabolism, such as changes in the subchondral bone, are increasingly recognized as mediators of pain and OA progression. Indeed, bone resorption is increased in patients with progressive OA. Increases in subchondral bone thickness, reductions in flexibility and reduced density of trabecular bone beneath the subchondral plate all occur early in the development of OA, and consequent increases in stress imparted to the articular cartilage contribute to OA progression. 66 Although peripheral blood mononuclear cells (PBMC) from patients with RA and OA have been shown to express miR-146a, 67, 68 overexpression of this miRNA in cultured PBMC isolated from healthy volunteers inhibited osteoclastogenesis in a dose-dependent manner. 69 Furthermore, intravenous injection of miR-146a prevented joint destruction in mice with collagen-induced arthritis. 69 miR-223 has also been implicated in osteoclastogenesis, controlling differentiation and function of RAW 264.7 cells (mouse osteoclast precursors) by repressing levels of the transcription factor nuclear factor 1 A-type. 70, 71 In mouse osteogenesis, miR-210 promoted osteoblast differentiation by inhibiting the activity of TGF-β type I receptor; 72 this miRNA had previously been associated with angiogenesis. 73 A newly identified miRNA, miR-2861, is highly expressed in primary mouse osteoblasts and promotes osteogenic differentiation through inhibition of Hdac5, increasing acetylation of the osteogenic master gene, Runx2. 74, 75 Molecular crosstalk between cartilage and bone is thought to increase as OA-related tissue degradation and aberrant vascularization increase the potential for direct communication between these tissues. Potentially, chondrocyte expression of miRNAs at the osteochondral junction might be important for maintaining cartilage-bone differentiation.
Clinical application
Lack of disease-modifying drugs in OA Several potential molecular targets for the treatment of OA, such as proteases, cell signalling molecules and transcription factors, have been identified in studies in humans and animal models, 35, [76] [77] [78] [79] [80] [81] [82] but clinical success in regu lating these molecules has thus far is induced in mice in response to proinflammatory mediators via NFκB, and it regulates cytokine signalling in a negative feedback loop involving downregulation of IRAK1 and TRAF6, and regulates osteoclastogenesis. Expression of miR-140 is reduced in response to proinflammatory mediators, and its loss impairs the balance of cartilage homeostasis. Moreover, miR-145 regulates miR-140, miR-675 and chondrogenic genes via Sox9. Therefore, administration of anti-miR-145, miR-140 and miR-146 into joint tissues might promote joint health. Other combinatorial miRNA targets in OA are likely to emerge with further research. Abbreviations: IRAK1, IL-1 receptor associated kinase 1; miRNA, microRNA; OA, osteoarthritis; NFκB, nuclear factor κB; TRAF6, TNF receptor associated factor 6.
been inadequate. Clinical trials of protease inhibitors as disease-modifying treatments in OA have been unsuc cessful, for example, owing to lack of efficacy or adverse effects. 83 Other potential targets in OA are even further from clinical application. The transcription factor HIF2α is an extensive regulator of OA development in mice and humans, directly inducing chondrocyte expression of genes such as RUNX2 and IHH. 79, 80 RUNX2 is another central player in OA pathogenesis, regulating ADAMTS5 expression 84 and hedgehog signalling. 85 How ever, methods to inactivate transcription factors in cartilage must address the problem of the avascular extracellular matrix that surrounds chondrocytes and impedes access to them, 86 which has not yet been overcome. Furthermore, it remains to be clinically demon strated that pharmacologically targeting expression of extracellular regulators and intracellular signalling mechanisms (such as FGF-18 and BMP-7) can achieve repair of joint destruction. 87 Delivery of siRNA and miRNA Owing to their size and strong anionic charge, short interfering RNA (siRNA) or double-stranded miRNA cannot pass through the plasma membrane, and key to realizing the clinical potential of these molecules is achieving adequate delivery to target cell types without cytotoxicity. Phase I-II clinical trials of siRNA are being conducted in some diseases, such as cancer and infection, but the develop ment of these potential therapies is not progressing well. Many problems remain to be overcome, such as an appropriate drug-delivery system, and off-target effects.
To enhance uptake of siRNA in difficult-to-transfect primary cell lines, Eguchi et al. 88 developed a delivery approach that uses a peptide transduction domaindouble-stranded RNA-binding domain (PTD-DRBD) fusion protein. Cationic peptides have been utilized for siRNA delivery; however, the compounds often aggregate and their potency is reduced because of their physicochemical properties. PTD-DRBD, which is designed to wrap around siRNA, shows high efficiency of siRNA delivery to several cell types. 88 Rapid siRNA-mediated effects in a large percentage of various primary and transformed cell lines were achieved, with no cyto toxicity, minimal off-target transcriptional changes and no induction of innate immune responses. 88 Nevertheless, novel approaches such as this one remain far from clinical use at present, and a full discussion of drug-delivery methods is beyond the scope of this manuscript.
Therapeutic potential of miRNA in OA Although miRNA-mediated downregulation of gene expression is relatively modest compared with that of siRNA, miRNAs seem able to fine-tune the expression of multiple genes, and might thus be a more useful tool than siRNA in complex diseases such as OA that involve 'interactomes' of molecular players. Indeed, simultaneously targeting multiple miRNAs that are involved in disease-relevant networks is likely to be the most effective clinical approach.
The approach to using miRNA as therapy depends on whether the aim is to restore levels of a downregulated miRNA (using a synthetic double-stranded miRNA), or to suppress expression of an aberrantly upregulated transcript, which can be blocked using a synthetic antisense miRNA ( Figure 1 ). As we have discussed, miR-140 might have therapeutic potential in OA, by regulating cartilage homeostasis. 35 On the basis of current bio informatic knowledge and the impact of depletion of miR-140 on the development of spontaneous OA in animals, we speculate that miR-140 targets multiples genes in addition to ADAMTS5. miR-146, meanwhile, is critical to terminating the inflammatory and catabolic pathways initiated by inflammatory cytokines such as IL-1β. 12 Similarly, inhibition of miR-145 in OA chondrocytes might have therapeutic potential because it is able to upregulate expression of cartilage-specific miRNAs and genes such as miR-140, miR-655 and Col2a1. 42 Thus, combined delivery of miRNAs to articular chondrocytes could produce synergistic inhibitory effects on OA patho genesis ( Figure 4 ). Little evidence of the potential therapeutic utility of other miRNAs in OA is currently available, but we expect that the accelerating pace of research in this field will rapidly lead to the identification of a series of potentially exciting molecules.
Although it would be ideal to target articular chondrocytes in OA, the unique challenge of the in vivo setting of these cells has not yet been overcome. Preventing inflammation in arthritis by synovial delivery of miRNA seems more immediately feasible than targeting cartilage. In mice with AIA (a model of RA), intra-articular injection of synthetic double-stranded miR-15a successfully induced synovial cell apoptosis by inhibiting expression of Bcl2. Labelled miR-15a injected into the articular space was subsequently detected in synovial cells, 89 but not in chondrocytes. Finally, as we discuss in the future perspectives section below, research into extracellular functions of miRNA might identify novel ways to target them, and potentially to harness endogenous systems that transport miRNA between cells.
Circulating miRNA as OA biomarkers Besides therapy, other potential clinical applications of miRNAs are as disease markers. Our discussion in this article has focused on the intracellular role of miRNAs in regulating gene expression, but extracellular miRNAs have been found in blood and other body fluids. 90 Pro filing circulating tumour-associated miRNAs, for example, is being considered as a surrogate for biopsy in cancer diagnosis, potentially extending screening to asymptomatic populations. Indeed, many studies have shown that extracellular miRNA levels in body fluids correlate with cancer. 91, 92 In PBMC from patients with RA, levels of miR-146a, miR-155, miR-132 and miR-16 were raised approximately twofold compared with cells from healthy donors. 67 In PBMC from patients with OA, the expression levels of miR-146a, miR-155, miR-181a, and miR-223 were significantly higher than cells from healthy donors. In particular, levels of miR-146a (P <0.01) and miR-223 (P <0.01) expression in the early stages of OA were significantly higher than at later stages. 68 Furthermore, Murata et al. 93 detected miRNAs in synovial fluid and plasma from patients with RA and OA; levels of miR-16 (P <0.01), miR-146a (P <0.05), miR-155 (P <0.05) and miR-223 (P <0.05) were significantly higher in RA synovial fluid than in OA samples, and levels of miR-16 and miR-146a in PBMC and plasma correlated with RA disease activity. Thus, miRNA in body fluids such as synovial fluids could be promising diagnostic biomarkers for joint disease, although none are yet proposed for this use in OA. Disease-specific and stage-specific profiles of extracellular miRNAs, furthermore, are expected to assist in characterization as well as diagnosis of disease in future.
Future perspectives Extracellular miRNAs are packaged in secretory microparticles such as exosomes, representing genetic material that is transferable between tissues and between individuals. 94 Thus, miRNAs might be not only intracellular regu latory molecules, but also paracrine regulatory factors, mediating cell-cell and tissue-tissue communication. In mice, exosomes derived from dendritic cells have been used to deliver systemically-injected miRNA to neurons, microglia and oligodendrocytes in the brain, with subsequent suppression of a target gene in Alzheimer disease. 95 Mechanisms involving transport and functions of exosomes containing extracellular miRNAs are, however, not well understood, and have not yet been investigated in joint cells and joint diseases. Study of extracellular miRNAs as a novel means of communication among joint tissue cells might provide new insights into the mechanisms of joint pathologies, which could lead to the identification of novel therapeutic targets and biomarkers in OA. Furthermore, such studies would not only pave the way for improved understanding and treatment of joint diseases, but would also, potentially, illuminate the general roles of extracellular miRNA signalling pathways in physiological and pathophysio logical conditions.
Conclusions
The complicated interactions between miRNAs and their multiple target genes are likely to have important roles in gene regulation and the control of pathophysiological pathways. Research into molecular mechanisms and gene networks, including regulators such as miRNAs, has led to the elucidation of OA pathogenesis pathways. Positive cascades of regulation of gene expression by transcription factors interact with negative regulation networks involving factors such as miRNAs in physiological and pathophysiological pathways. Few miRNAs (among them miR-140) have been studied in OA, but the number of potential clinical targets in this disease is likely to increase. Developments in targeting miRNAs in other diseases, as well as advances in delivering therapies to joint tissues, are expected to aid clinical development of miRNA-based therapies in OA. Furthermore, circulating miRNAs might be useful for clinical applications including diagnosis, and offer novel methods for intracellular delivery of therapeutic molecules.
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